Nasus Pharma vs Prestige Consumer Healthcare
Nasus Pharma and Prestige Consumer Healthcare are similar in size: $1.24bn and $1.09bn of revenue in their latest fiscal years. Prestige Consumer Healthcare kept more of each dollar of sales as profit: a net margin of 17.5% against -0.5%.
| Latest fiscal year | Nasus PharmaNSRX, 2025 | Prestige Consumer HealthcarePBH, 2026 |
|---|---|---|
| Revenue | $1.24bn | $1.09bn |
| Revenue growth | — | -4.3% |
| Net income | −$5.9m | $190m |
| Operating margin | -0.4% | — |
| Net margin | -0.5% | 17.5% |
| Return on equity | — | 10.2% |
| Free cash flow | −$4.9m | $246m |
| Cash | $1.2m | $63.9m |
| Total debt | $0 | $1.00bn |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $156m |
| Employees | — | 890 |
| Market value | $28.6m | $2.34bn |
| Price vs our value range | — | Within our value range |
| Moat score | — | 67 (Moderate) |
| Insider trades, 12 months | 3 buys, 0 sales | 0 buys, 8 sales |